Form 4: Acasti Pharma Inc. Executive Granted Stock Options
SEC Form 4 Filing
Amresh Kumar, VP of Clinical Operations at Acasti Pharma Inc., was granted stock options on May 6, 2024.
Summary
- Amresh Kumar, VP of Clinical Operations at Acasti Pharma Inc., filed a Form 4.
- The filing reports a transaction where Mr. Kumar was granted 19,740 stock options on May 6, 2024.
- The exercise price of the options is $2.96.
- The options vest quarterly in equal installments over a 36-month period.
- The options expire on May 6, 2034.
Sentiment
Score: 6
Explanation: The document is a routine filing related to executive compensation. It is neutral in tone and doesn't contain information that would significantly impact investor sentiment.
Positives
- The granting of stock options aligns the executive's interests with those of the shareholders.
Industry Context
Stock option grants are a common practice in the pharmaceutical industry to incentivize executives and align their interests with the long-term success of the company.
Key Dates
| Date | Description |
|---|---|
| 05/06/2024 | Date of stock options grant |
| 05/06/2034 | Expiration date of stock options |
| 05/08/2024 | Date of Form 4 signature |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.